###begin article-title 0
Modulation of muscle contraction by a cell-permeable peptide
###end article-title 0
###begin p 1
###xml 0 16 0 16 <sc xmlns:xlink="http://www.w3.org/1999/xlink">Gisela T&#252;nnemann</sc>
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sc>Gisela T&#252;nnemann</sc></bold>
###xml 433 433 433 433 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_238_Figa_HTML" id="MO1"/>
Gisela Tunnemann studied chemistry at the Carl von Ossietzky-University in Oldenburg, Germany. She is presently working in the research group "Molecular and Cell Biology of the (Epi)genome" at the Max-Delbruck-Center for Molecular Medicine in Berlin, Germany. Her research interests include peptide delivery into living cells, mechanistical aspects of the translocation event of cell-penetrating peptides, and cell cycle regulation.
###end p 1
###begin p 2
###xml 0 11 0 11 <sc xmlns:xlink="http://www.w3.org/1999/xlink">Ingo Morano</sc>
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sc>Ingo Morano</sc></bold>
###xml 507 507 507 507 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_238_Figb_HTML" id="MO2"/>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 82 87 <span type="species:ncbi:9606">Human</span>
Ingo Morano received his Ph.D. in human sciences and postdoctoral Habilitation in Human Physiology from the Medical Faculty of the University of Heidelberg. He is presently Professor for Molecular Clinical Physiology at the Medical Faculty of the Humboldt University (Charite), Berlin, and leader of the "Molecular Muscle Physiology Group" at the Max-Delbruck-Center, Berlin. His research interests include expression, regulation, and function of contractile handling proteins in smooth and cardiac muscle.
###end p 2
###begin p 3
###xml 492 494 492 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 884 886 884 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1073 1075 1073 1075 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 267 270 <span type="species:ncbi:10116">rat</span>
###xml 417 422 <span type="species:ncbi:9606">human</span>
In contrast to immortal cell lines, primary cells are hardly susceptible to intracellular delivery methods such as transfection. In this study, we evaluated the direct delivery of several cell-permeable peptides under noninvasive conditions into living primary adult rat cardiomyocytes. We specifically monitored the functional effects of a cell-permeable peptide containing the 15 amino acid N-terminal peptide from human ventricular light chain-1 (VLC-1) on contraction and intracellular Ca2+ signals after electrical stimulation in primary adult cardiomyocytes. The transducible VLC-1 variant was taken up by cardiomyocytes within 5 min with more than 95% efficiency and localized to sarcomeric structures. Analysis of the functional effects of the cell-permeable VLC-1 revealed an enhancement of the intrinsic contractility of cardiomyocytes without affecting the intracellular Ca2+. Therefore, peptide transduction mediated by cell-penetrating peptides represents not only a unique strategy to enhance heart muscle function with no secondary effect on intracellular Ca2+ but also an invaluable tool for the modulation and manipulation of protein interactions in general and in primary cells.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1294 1296 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1533 1535 1533 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1956 1958 1956 1958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 2086 2087 2086 2087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 2089 2090 2089 2090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 2091 2092 2091 2092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 2094 2096 2094 2096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 2182 2184 2182 2184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 2186 2188 2186 2188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 2218 2220 2218 2220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 2813 2815 2813 2815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1031 1059 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 1061 1064 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2591 2596 <span type="species:ncbi:9606">human</span>
###xml 2836 2841 <span type="species:ncbi:9606">human</span>
###xml 2992 2995 <span type="species:ncbi:10116">rat</span>
Therapeutical delivery of protein or peptides into living primary cells is hampered by the lack of a suitable and efficient method for the introduction of macromolecules. Most commonly used transfections methods work in immortalized cells but mostly fail in primary cells or require specialized and time-consuming protocols, i.e., production of viral vectors. Moreover, the limited life span of primary cells often does not provide sufficient time for expression of gene products and subsequent analysis of their effects. Physical methods such as microinjection and bead loading are highly invasive procedures and are not tolerated by several cell types. It has been known for quite some time that basic proteins like histones or poly-ornithine as well as stretches of basic amino acids within proteins aid the uptake of proteins into mammalian cells [14, 17, 20, 30]. In the 1990s, transducible peptides like penetratin-1 from the homeodomain of Antennapedia [11] and amino acids 48-57 from the transactivator of transcription of human immunodeficiency virus (HIV)-1 [14] were identified and exploited to introduce drugs or biological macromolecules into mammalian cells. Together with other native and synthetic transducing peptides, they are referred to as cell-penetrating peptides (CPPs) [12]. However, it became evident that the invasive methods used to analyze the transduction mediated by CPPs or effects of interconnected cargoes had led to overestimated transduction results and overrated effects of cargoes fused to CPPs [27]. Nevertheless, CPPs mediate the introduction of fused cargoes into living cells, with cargo-dependent mechanistical differences. One uptake mechanism can be described as a slow adsorptive endocytosis and is preferentially used by globular proteins, whereas small compounds like peptides linked to CPPs favor a rapid membrane potential-dependent uptake with overall intracellular availability of the transduced species [33]. CPP-mediated peptide transduction has recently been used to deliver cardioprotective peptides derived from protein kinase C [4, 7-9, 24], the antiapoptotic BH4 peptide derived from the apoptosis regulator protein Bcl-xL [26, 28] and a Nox2-derived peptide [34] into isolated cardiomyocytes or whole hearts. We have tested the feasibility of this approach to study muscle function in living adult primary cardiomyocytes. Therefore, we targeted the interaction between actin and the essential myosin light chain (MLC-1) of cardiac type II myosin by a peptide competition approach. Transgenic overexpression of the N terminus of the human ventricular MLC-1 (residues 1-15; hereafter termed VLC-1), which binds to actin and targets actin/MLC-1 interaction, significantly increased the magnitude and kinetics of the contraction of isolated perfused hearts [21]. We fused the same human VLC-1 peptide to the TAT CPP (VLC-1-TAT) and investigated its uptake, intracellular distribution, and functional consequences in primary living adult rat cardiomyocytes.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin p 8
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Isolation of adult rat cardiomyocytes</bold>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 19 22 <span type="species:ncbi:10116">rat</span>
###xml 87 91 <span type="species:ncbi:10116">rats</span>
Isolation of adult rat cardiomyocytes Primary cultures of cardiomyocytes from male WKY rats aged 3 months were performed as described previously [1].
###end p 8
###begin p 9
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Peptides</bold>
###xml 42 43 42 43 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 80 81 80 81 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 127 128 127 128 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 198 199 198 199 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 404 414 404 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rrrqrrkkrg</italic>
###xml 420 421 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 438 449 438 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">araqraaaray</italic>
###xml 471 481 471 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rrrqrrkkrg</italic>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
Peptides The peptides consisted of either l-amino acids (capital letters) or of d-amino acids (lower case letters). In case of d-amino acid peptides, functional motifs were synthesized as retro-all d-variants (underlined) to maintain their functionality. Peptides were either labeled with the fluorophore 5,6-carboxy-tetramethylrhodamine (TAMRA) or fluorescein isothiocyanate (FITC). TAT (TAMRA- or FITC-rrrqrrkkrg), PTD4 [23, 33] (TAMRA-araqraaaray), and TAT-p21 (TAMRA-rrrqrrkkrgaaAGRKRRQTSMTDFYHSKRRLIFSa-amide) [33] were labeled directly at their N termini with the indicated fluorophores (Peptide Speciality Laboratories, Heidelberg). In the case of VLC-1 (MAPKKPEPKKSSAKA-C-TAMRA-ME-amide) and VLC-1-TAT (MAPKKPEPKDDAKAPAGRKKRRQRRR-C-TAMRA-ME-amide; Biosyntan, Berlin) the TAMRA fluorophore was coupled via an additional cysteine at the C terminus leaving the N terminus free for the interaction with actin.
###end p 9
###begin p 10
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Uptake of transducible peptides and controls</bold>
###xml 757 758 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 935 936 933 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1212 1214 1210 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1221 1222 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1460 1466 1458 1464 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 2073 2074 2070 2071 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2100 2101 2097 2098 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2135 2136 2132 2133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2162 2163 2159 2160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2230 2231 2226 2227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 2233 2234 2229 2230 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2282 2283 2278 2279 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 2321 2322 2316 2317 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 2408 2417 2403 2412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 2427 2432 2421 2426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Stars</italic>
###xml 2457 2467 2451 2461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 2482 2483 2476 2477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 2521 2523 2515 2517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PC</italic>
###xml 2540 2542 2534 2536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NP</italic>
###xml 1466 2554 1464 2548 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="11">Peptide uptake and intracellular distribution in living adult cardiomyocytes. To study the uptake capacity of different compounds into primary rat cardiomyocytes, different fluorescent compounds were directly added for 1&#160;h to the medium or buffer of freshly isolated cardiomyocytes. After the incubation period, confocal images of the cells were taken without exchange of the medium and after removal of the fluorescent solution and exchange against the fresh medium. Internalization into healthy adult cardiomyocytes occurred after application of 10&#160;&#956;M of the transducible peptides FITC-TAT shown at low (<bold>a</bold>) and high magnification (<bold>b</bold>) and TAMRA-TAT-p21 shown at low (<bold>c</bold>) and high magnification (<bold>d</bold>) but not with application of 10&#160;&#956;M of a basic control peptide PTD<sub>4</sub> (<bold>e</bold>). Moreover, 0.5% of the vital dye trypan blue (<bold>f</bold>) or 10&#160;&#956;M of the TAMRA-fluorophore (<bold>g</bold>) itself were not able to enter healthy cardiomyocytes (rod-shaped cells in culture). <italic>Scale bar</italic>, 10&#160;&#956;m. <italic>Stars</italic> indicate the nuclei and <italic>arrowheads</italic> the nucleoli (<italic>N</italic>) in the higher magnification images. <italic>PC</italic> Phase contrast, <italic>NP</italic> nucleoplasm</p>
###xml 1466 2554 1464 2548 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="11">Peptide uptake and intracellular distribution in living adult cardiomyocytes. To study the uptake capacity of different compounds into primary rat cardiomyocytes, different fluorescent compounds were directly added for 1&#160;h to the medium or buffer of freshly isolated cardiomyocytes. After the incubation period, confocal images of the cells were taken without exchange of the medium and after removal of the fluorescent solution and exchange against the fresh medium. Internalization into healthy adult cardiomyocytes occurred after application of 10&#160;&#956;M of the transducible peptides FITC-TAT shown at low (<bold>a</bold>) and high magnification (<bold>b</bold>) and TAMRA-TAT-p21 shown at low (<bold>c</bold>) and high magnification (<bold>d</bold>) but not with application of 10&#160;&#956;M of a basic control peptide PTD<sub>4</sub> (<bold>e</bold>). Moreover, 0.5% of the vital dye trypan blue (<bold>f</bold>) or 10&#160;&#956;M of the TAMRA-fluorophore (<bold>g</bold>) itself were not able to enter healthy cardiomyocytes (rod-shaped cells in culture). <italic>Scale bar</italic>, 10&#160;&#956;m. <italic>Stars</italic> indicate the nuclei and <italic>arrowheads</italic> the nucleoli (<italic>N</italic>) in the higher magnification images. <italic>PC</italic> Phase contrast, <italic>NP</italic> nucleoplasm</p></caption>
###xml 2554 2554 2548 2548 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_238_Fig1_HTML" id="MO3"/>
###xml 1460 2554 1458 2548 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="11">Peptide uptake and intracellular distribution in living adult cardiomyocytes. To study the uptake capacity of different compounds into primary rat cardiomyocytes, different fluorescent compounds were directly added for 1&#160;h to the medium or buffer of freshly isolated cardiomyocytes. After the incubation period, confocal images of the cells were taken without exchange of the medium and after removal of the fluorescent solution and exchange against the fresh medium. Internalization into healthy adult cardiomyocytes occurred after application of 10&#160;&#956;M of the transducible peptides FITC-TAT shown at low (<bold>a</bold>) and high magnification (<bold>b</bold>) and TAMRA-TAT-p21 shown at low (<bold>c</bold>) and high magnification (<bold>d</bold>) but not with application of 10&#160;&#956;M of a basic control peptide PTD<sub>4</sub> (<bold>e</bold>). Moreover, 0.5% of the vital dye trypan blue (<bold>f</bold>) or 10&#160;&#956;M of the TAMRA-fluorophore (<bold>g</bold>) itself were not able to enter healthy cardiomyocytes (rod-shaped cells in culture). <italic>Scale bar</italic>, 10&#160;&#956;m. <italic>Stars</italic> indicate the nuclei and <italic>arrowheads</italic> the nucleoli (<italic>N</italic>) in the higher magnification images. <italic>PC</italic> Phase contrast, <italic>NP</italic> nucleoplasm</p></caption><graphic position="anchor" xlink:href="109_2007_238_Fig1_HTML" id="MO3"/></fig>
###xml 1609 1612 <span type="species:ncbi:10116">rat</span>
Uptake of transducible peptides and controls To analyze the transduction ability of different compounds into living adult ventricular cardiomyocytes, the primary cells were plated into a laminin-coated mu-slide eight-well ibiTreat (ibidi, Martinsried) or four-well labtek (Nunc, Wiesbaden) microscopy observation chamber. The respective peptides and controls were added directly to Hank's balanced salts solution buffered with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.4 (HBSS) or medium and gently shaken to yield a final concentration of 10 muM in case of the peptides and 5,6-TAMRA-fluorophore. Trypan blue (Sigma-Aldrich) was added to a final concentration of 0.5% (v/v) to the HBSS buffer. For the experiments summarized in Fig. 1 confocal images were acquired 1 h after addition of the respective compounds to living cardiomyocytes. To study the intracellular localization of transducible peptides in Fig. 3, after 15 min of peptide incubation, the medium was removed, and the cells were washed twice with the HBSS buffer. For subsequent confocal image collection, the cells were kept in medium or buffer. To study the effect of the peptide on muscle contraction and intracellular Ca2+ (Fig. 4), cardiomyocytes were electrically stimulated (see below) to permit the access of the peptides to all actin molecules with potential binding sites. During confocal image collection, the electric stimulation was temporarily switched off. Fig. 1Peptide uptake and intracellular distribution in living adult cardiomyocytes. To study the uptake capacity of different compounds into primary rat cardiomyocytes, different fluorescent compounds were directly added for 1 h to the medium or buffer of freshly isolated cardiomyocytes. After the incubation period, confocal images of the cells were taken without exchange of the medium and after removal of the fluorescent solution and exchange against the fresh medium. Internalization into healthy adult cardiomyocytes occurred after application of 10 muM of the transducible peptides FITC-TAT shown at low (a) and high magnification (b) and TAMRA-TAT-p21 shown at low (c) and high magnification (d) but not with application of 10 muM of a basic control peptide PTD4 (e). Moreover, 0.5% of the vital dye trypan blue (f) or 10 muM of the TAMRA-fluorophore (g) itself were not able to enter healthy cardiomyocytes (rod-shaped cells in culture). Scale bar, 10 mum. Stars indicate the nuclei and arrowheads the nucleoli (N) in the higher magnification images. PC Phase contrast, NP nucleoplasm
###end p 10
###begin p 11
###xml 607 608 606 607 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 634 635 633 634 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 669 670 668 669 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 696 697 695 696 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 764 765 762 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 767 768 765 766 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 816 817 814 815 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 855 856 852 853 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 942 951 939 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scale bar</italic>
###xml 961 966 957 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Stars</italic>
###xml 991 1001 987 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowheads</italic>
###xml 1016 1017 1012 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1055 1057 1051 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PC</italic>
###xml 1074 1076 1070 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NP</italic>
###xml 143 146 <span type="species:ncbi:10116">rat</span>
Peptide uptake and intracellular distribution in living adult cardiomyocytes. To study the uptake capacity of different compounds into primary rat cardiomyocytes, different fluorescent compounds were directly added for 1 h to the medium or buffer of freshly isolated cardiomyocytes. After the incubation period, confocal images of the cells were taken without exchange of the medium and after removal of the fluorescent solution and exchange against the fresh medium. Internalization into healthy adult cardiomyocytes occurred after application of 10 muM of the transducible peptides FITC-TAT shown at low (a) and high magnification (b) and TAMRA-TAT-p21 shown at low (c) and high magnification (d) but not with application of 10 muM of a basic control peptide PTD4 (e). Moreover, 0.5% of the vital dye trypan blue (f) or 10 muM of the TAMRA-fluorophore (g) itself were not able to enter healthy cardiomyocytes (rod-shaped cells in culture). Scale bar, 10 mum. Stars indicate the nuclei and arrowheads the nucleoli (N) in the higher magnification images. PC Phase contrast, NP nucleoplasm
###end p 11
###begin p 12
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Microscopy, image acquisition, and analysis</bold>
Microscopy, image acquisition, and analysis Confocal images were acquired with a Zeiss laser scanning microscope LSM510 Meta mounted on an Axiovert 200M inverted microscope using a 63x phase-contrast oil immersion plan-apochromat objective NA1.4 or a 100x phase-contrast oil immersion plan-neofluar objective NA1.3. For all settings, the main beam splitter was HFT UV/488/543/633, and the specific parameters for the single fluorophores were: FITC, excited at 488 nm light, detected with a 500-530-nm bandpass filter; TAMRA or rhodamine excited at 543 nm, detected with 565-615 bandpass filter; and trypan blue, excited with 633 nm, detected with 650 longpass filter. Phase-contrast images were recorded with excitation at 488 nm and detection in the transmission channel. Laser power for observation was typically 1-5% (488 nm, 25 mW) and 50-60% (543 nm, 1 mW) unless otherwise indicated. Settings were adjusted in a way that image pixels were not over- or underexposed with the range indicator function in the Zeiss LSM image acquisition and examiner software version 3.2.
###end p 12
###begin p 13
###xml 46 48 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Measurement of cardiomyocyte shortening and Ca<sup>2+</sup> transients</bold>
Measurement of cardiomyocyte shortening and Ca2+ transients Attached cardiomyocytes were washed with HBSS. Cells were loaded with Fura-2-AM for 30 min at room temperature in the dark. The dye solution was removed, and cells were left on HBSS for another 15 min. Only cardiomyocytes of optically intact rod-shaped morphology with clear cross-striation were analyzed. Cardiomyocytes were electrically stimulated until a stable steady-state contraction and Fura-2 signal could be monitored.
###end p 13
###begin p 14
###xml 382 384 376 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Cell shortening and Fura-2 signals were simultaneously measured at 30degreesC on an Ionoptix Contractility and Fluorescence System (Ionoptix). Cardiomyocytes were electrically stimulated with bipolar pulses of 5 ms duration at 1 Hz. Cell shortening, expressed as percentage of resting cell length, was measured using the video-edge technique at a sampling rate of 240 per second. Ca2+ transients were monitored as ratio of fluorescence emission at 510 nm was obtained by alternate excitation at 340 and 380 nm (340/380 ratio). Data files from 15 consecutive beats recorded at intervals were averaged for analysis. Subsequently, the cardiomyocytes were incubated with the peptides for 15 min without electrical stimulation. The peptide was then removed by replacing the peptide-containing HBSS buffer with normal HBSS buffer without the peptide. The cardiomyocytes were subsequently electrically stimulated, and both the shortening and Fura-2 signals were simultaneously recorded. The effect of the peptide on shortening amplitude and the Fura-2 signal was expressed in percent change compared to the steady-state signals obtained in the preincubation period.
###end p 14
###begin title 15
Results and discussion
###end title 15
###begin p 16
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
We recently demonstrated by live-cell confocal microscopy that the TAT CPP was able to shuttle fused peptides into primary blood cells and subsequently modulated their functional properties [10]. In this study, we tested whether TAT CPP could penetrate and if a peptide derived from the N terminus of VLC-1 fused to TAT is able to modulate the contractile function of primary adult cardiomyocytes.
###end p 16
###begin p 17
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 621 628 621 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WAF/CIP</sup>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 768 775 768 775 <sup xmlns:xlink="http://www.w3.org/1999/xlink">WAF/CIP</sup>
###xml 1022 1023 1022 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1110 1112 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1114 1116 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1118 1120 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 1232 1233 1232 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1235 1237 1235 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1315 1316 1315 1316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1359 1361 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1363 1365 1363 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 1526 1527 1526 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1597 1598 1597 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1633 1634 1633 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1874 1875 1874 1875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 2091 2092 2091 2092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 2220 2222 2220 2222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 2224 2226 2224 2226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 2228 2230 2228 2230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 281 286 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 759 764 <span type="species:ncbi:9606">human</span>
Different basic peptides were incubated with freshly prepared cultures of cardiomyocytes, and peptide internalization was analyzed live by laser-scanning confocal microscopy. The fluorescently labeled minimal transduction domain TAT CPP of the transactivator of transcription from HIV-1 was readily taken up into cardiomyocytes and displayed a strong affinity to the nuclear compartment (Fig. 1a). It could also be visualized in a punctate pattern throughout the entire cardiomyocyte (Fig. 1a). To determine whether the TAT CPP is able to shuttle an attached peptide into cardiomyocytes, we used the TAMRA-labeled TAT-p21WAF/CIP (TAT-p21) fusion peptide [33], which in addition to the transducing moiety contains 26 amino acids derived from the C terminus of human p21WAF/CIP protein. The uptake of this cargo peptide (assessed by appearance in nucleoli) occurred on a timescale of 5 to 10 min after peptide application. Its pattern of localization inside the cardiomyocytes was similar than that seen for TAT alone (Fig. 1c). Basic amino acid residues are a prerequisite for the transduction ability of CPPs [13, 25, 35], and peptides containing a minimum of six basic amino acids have been shown to traverse biological membranes [5, 18]. As a nontransducing control peptide, we chose the TAMRA-labeled peptide PTD4, which contains three arginines in total [23, 33]. More than 1 h after application of this peptide to the cardiomyocyte culture, none of the healthy intact cardiomyocytes took up the fluorescent peptide (Fig. 1e). Similar results were obtained for the vital dye trypan blue (Fig. 1f) and the TAMRA fluorophore (Fig. 1g). Approximately 5% of cardiomyocytes in the cultures were dead or harmed (visible in the phase-contrast images as not rod shaped and with no striations). These cells were flooded with both the CPPs as well as any other control dyes (Fig. 1c,e-g). The cell-permeable TAT-derived peptides displayed a similar enrichment in the nuclear compartment with strong accumulation inside nucleoli (arrowheads) as can be seen in the higher magnification images (Fig. 1b,d). This intranuclear distribution is basically determined by the TAT moiety, which includes a nuclear localization sequence [22, 29, 33].
###end p 17
###begin p 18
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 850 851 850 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 853 854 853 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 985 986 985 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1397 1399 1397 1399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1443 1449 1443 1449 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1558 1559 1558 1559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1610 1616 1610 1616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">orange</italic>
###xml 1636 1642 1636 1642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 1663 1664 1663 1664 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1718 1724 1718 1724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">violet</italic>
###xml 1740 1743 1740 1743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1798 1800 1798 1800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD</italic>
###xml 1823 1825 1823 1825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ND</italic>
###xml 1880 1885 1880 1885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1959 1962 1959 1962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 2181 2192 2181 2192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow ball</italic>
###xml 2219 2225 2219 2225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">orange</italic>
###xml 2475 2477 2475 2477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 2569 2571 2569 2571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 2573 2575 2573 2575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 1449 2576 1449 2576 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">Molecular hypothesis for the enhancement of cardiomyocyte contractility by the cell-permeable VLC-1 peptide. <bold>a</bold> Primary sequence of VLC-1-TAT peptide color-coded <italic>orange</italic> for the VLC-1- and <italic>yellow</italic> for the TAT-moiety. <bold>b</bold> Schematic sliding filament model displaying actin in <italic>violet</italic> and the MHC in <italic>red</italic>. The higher magnification shows the catalytic domain (<italic>CD</italic>) and the neck domain (<italic>ND</italic>) of one molecule of the MHC. MLC proteins are colored <italic>green</italic> with the N-terminal SE inside the essential MLC-1 protein highlighted in <italic>red</italic>. Upon intramolecular conformational changes in the CD of MHC, the ND swings out, exposing the SE of MLC-1 to an actin molecule in direction to the Z-line. Treatment of cardiomyocytes with the transducible TAT peptide (<italic>yellow ball</italic>) fused to the SE-peptide (<italic>orange</italic>) blocks potential binding sites of the native MLC-1 N terminus. After the MHC rearrangement, the MLC-1 protein can no longer interact with actin and downregulate the myosin motor activity. The scheme is based on the pre- and postpower stroke model [<xref ref-type="bibr" rid="CR19">19</xref>] developed with respect to crystallographic data on the Dicytostelium myosin motor domain [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]</p>
###xml 1449 2576 1449 2576 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="19">Molecular hypothesis for the enhancement of cardiomyocyte contractility by the cell-permeable VLC-1 peptide. <bold>a</bold> Primary sequence of VLC-1-TAT peptide color-coded <italic>orange</italic> for the VLC-1- and <italic>yellow</italic> for the TAT-moiety. <bold>b</bold> Schematic sliding filament model displaying actin in <italic>violet</italic> and the MHC in <italic>red</italic>. The higher magnification shows the catalytic domain (<italic>CD</italic>) and the neck domain (<italic>ND</italic>) of one molecule of the MHC. MLC proteins are colored <italic>green</italic> with the N-terminal SE inside the essential MLC-1 protein highlighted in <italic>red</italic>. Upon intramolecular conformational changes in the CD of MHC, the ND swings out, exposing the SE of MLC-1 to an actin molecule in direction to the Z-line. Treatment of cardiomyocytes with the transducible TAT peptide (<italic>yellow ball</italic>) fused to the SE-peptide (<italic>orange</italic>) blocks potential binding sites of the native MLC-1 N terminus. After the MHC rearrangement, the MLC-1 protein can no longer interact with actin and downregulate the myosin motor activity. The scheme is based on the pre- and postpower stroke model [<xref ref-type="bibr" rid="CR19">19</xref>] developed with respect to crystallographic data on the Dicytostelium myosin motor domain [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]</p></caption>
###xml 2576 2576 2576 2576 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_238_Fig2_HTML" id="MO4"/>
###xml 1443 2576 1443 2576 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="19">Molecular hypothesis for the enhancement of cardiomyocyte contractility by the cell-permeable VLC-1 peptide. <bold>a</bold> Primary sequence of VLC-1-TAT peptide color-coded <italic>orange</italic> for the VLC-1- and <italic>yellow</italic> for the TAT-moiety. <bold>b</bold> Schematic sliding filament model displaying actin in <italic>violet</italic> and the MHC in <italic>red</italic>. The higher magnification shows the catalytic domain (<italic>CD</italic>) and the neck domain (<italic>ND</italic>) of one molecule of the MHC. MLC proteins are colored <italic>green</italic> with the N-terminal SE inside the essential MLC-1 protein highlighted in <italic>red</italic>. Upon intramolecular conformational changes in the CD of MHC, the ND swings out, exposing the SE of MLC-1 to an actin molecule in direction to the Z-line. Treatment of cardiomyocytes with the transducible TAT peptide (<italic>yellow ball</italic>) fused to the SE-peptide (<italic>orange</italic>) blocks potential binding sites of the native MLC-1 N terminus. After the MHC rearrangement, the MLC-1 protein can no longer interact with actin and downregulate the myosin motor activity. The scheme is based on the pre- and postpower stroke model [<xref ref-type="bibr" rid="CR19">19</xref>] developed with respect to crystallographic data on the Dicytostelium myosin motor domain [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]</p></caption><graphic position="anchor" xlink:href="109_2007_238_Fig2_HTML" id="MO4"/></fig>
###xml 191 196 <span type="species:ncbi:9606">human</span>
Having shown that CPP TAT was able to shuttle fused peptides into living cardiomyocytes, we designed a transducible peptide comprising the actin-binding element of the ventricular isoform of human MLC-1 (VLC-1), i.e., the N-terminal residues 1-15 (VLC-1 peptide) connected to TAT, termed VLC-1-TAT (Fig. 2). The hearts of transgenic animals harboring minigenes encoding for the VLC-1 peptide revealed enhanced myosin motor activity and positive inotropic effects [21]. A possible molecular mechanism for the increase in myosin motor activity and contractility is illustrated in the scheme in Fig. 2. MLC-1 isoforms of vertebrate striated muscle play a regulatory role in myosin motor function: The N-terminal part of MLC-1 contains a sticky element (SE), which consists of several positively charged amino acids that bind to the C terminus of actin [3, 6, 16, 31]. The 46 N-terminal amino acids of MLC-1 have previously been modeled on the basis of contemporary crystallographic data [2]. Interactions between the sticky MLC-1 element and actin serve as a negative modulator and decrease the activity of the myosin motor domain. Intracellular delivery of a synthetic sticky MLC-1 element by TAT-mediated transduction therefore would antagonize MLC-1/actin interaction. We predict this would increase myosin motor activity and enhance the shortening amplitude without change of the systolic free Ca2+ activation level of intact cardiomyocytes. Fig. 2Molecular hypothesis for the enhancement of cardiomyocyte contractility by the cell-permeable VLC-1 peptide. a Primary sequence of VLC-1-TAT peptide color-coded orange for the VLC-1- and yellow for the TAT-moiety. b Schematic sliding filament model displaying actin in violet and the MHC in red. The higher magnification shows the catalytic domain (CD) and the neck domain (ND) of one molecule of the MHC. MLC proteins are colored green with the N-terminal SE inside the essential MLC-1 protein highlighted in red. Upon intramolecular conformational changes in the CD of MHC, the ND swings out, exposing the SE of MLC-1 to an actin molecule in direction to the Z-line. Treatment of cardiomyocytes with the transducible TAT peptide (yellow ball) fused to the SE-peptide (orange) blocks potential binding sites of the native MLC-1 N terminus. After the MHC rearrangement, the MLC-1 protein can no longer interact with actin and downregulate the myosin motor activity. The scheme is based on the pre- and postpower stroke model [19] developed with respect to crystallographic data on the Dicytostelium myosin motor domain [15, 32]
###end p 18
###begin p 19
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">orange</italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 214 215 214 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">violet</italic>
###xml 291 294 291 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 349 351 349 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD</italic>
###xml 374 376 374 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ND</italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 510 513 510 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 732 743 732 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow ball</italic>
###xml 770 776 770 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">orange</italic>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1120 1122 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1124 1126 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
Molecular hypothesis for the enhancement of cardiomyocyte contractility by the cell-permeable VLC-1 peptide. a Primary sequence of VLC-1-TAT peptide color-coded orange for the VLC-1- and yellow for the TAT-moiety. b Schematic sliding filament model displaying actin in violet and the MHC in red. The higher magnification shows the catalytic domain (CD) and the neck domain (ND) of one molecule of the MHC. MLC proteins are colored green with the N-terminal SE inside the essential MLC-1 protein highlighted in red. Upon intramolecular conformational changes in the CD of MHC, the ND swings out, exposing the SE of MLC-1 to an actin molecule in direction to the Z-line. Treatment of cardiomyocytes with the transducible TAT peptide (yellow ball) fused to the SE-peptide (orange) blocks potential binding sites of the native MLC-1 N terminus. After the MHC rearrangement, the MLC-1 protein can no longer interact with actin and downregulate the myosin motor activity. The scheme is based on the pre- and postpower stroke model [19] developed with respect to crystallographic data on the Dicytostelium myosin motor domain [15, 32]
###end p 19
###begin p 20
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 860 866 860 866 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 957 958 957 958 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1394 1395 1393 1394 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1498 1509 1497 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 1642 1653 1641 1652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 1656 1657 1655 1656 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1753 1764 1752 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 1771 1782 1770 1781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 1902 1907 1901 1906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 1960 1964 1959 1963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gray</italic>
###xml 1969 1972 1968 1971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 2138 2149 2137 2148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">light bands</italic>
###xml 866 2174 866 2173 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21">Transduction and intracellular localization of VLC-1-TAT in isolated adult cardiomyocytes. <bold>a</bold> Scheme for the application of the VLC-1-derived peptides and confocal imaging. Peptides were applied at a concentration of 1&#160;&#956;M, incubated for 15&#160;min to freshly isolated cardiomyocytes. After removal of the peptide solution, the cells were washed twice and kept in buffer or medium for direct live-cell confocal imaging microscopy. Subsequently, the transduced cardiomyocytes were electrically stimulated with 1&#160;Hz for maximally 1&#160;h. <bold>b</bold> The negative control peptide TAMRA-labeled VLC-1 stained only dead cardiomyocytes (low magnification, <italic>upper panel</italic>) but failed to get internalized into healthy cardiomyocytes even when 100% laser power was used to detect potentially weak signals (<italic>lower panel</italic>). <bold>c</bold> Application of TAT-VLC-1 to living cardiomyocytes led to rapid internalization of the peptide (<italic>upper panel</italic>). The <italic>lower panel</italic> shows transduced VLC-1-TAT at higher magnification in an overlay of the phase contrast and the TAMRA-fluorescence. The <italic>arrow</italic> indicates the direction of the intensity profile of <italic>gray</italic> and <italic>red</italic> intensities in the line scan for the localization analysis of VLC-1-TAT, which was present at sarcomeric structures with enrichment at the actin-containing I-bands (<italic>light bands</italic> in phase-contrast image)</p>
###xml 866 2174 866 2173 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21">Transduction and intracellular localization of VLC-1-TAT in isolated adult cardiomyocytes. <bold>a</bold> Scheme for the application of the VLC-1-derived peptides and confocal imaging. Peptides were applied at a concentration of 1&#160;&#956;M, incubated for 15&#160;min to freshly isolated cardiomyocytes. After removal of the peptide solution, the cells were washed twice and kept in buffer or medium for direct live-cell confocal imaging microscopy. Subsequently, the transduced cardiomyocytes were electrically stimulated with 1&#160;Hz for maximally 1&#160;h. <bold>b</bold> The negative control peptide TAMRA-labeled VLC-1 stained only dead cardiomyocytes (low magnification, <italic>upper panel</italic>) but failed to get internalized into healthy cardiomyocytes even when 100% laser power was used to detect potentially weak signals (<italic>lower panel</italic>). <bold>c</bold> Application of TAT-VLC-1 to living cardiomyocytes led to rapid internalization of the peptide (<italic>upper panel</italic>). The <italic>lower panel</italic> shows transduced VLC-1-TAT at higher magnification in an overlay of the phase contrast and the TAMRA-fluorescence. The <italic>arrow</italic> indicates the direction of the intensity profile of <italic>gray</italic> and <italic>red</italic> intensities in the line scan for the localization analysis of VLC-1-TAT, which was present at sarcomeric structures with enrichment at the actin-containing I-bands (<italic>light bands</italic> in phase-contrast image)</p></caption>
###xml 2174 2174 2173 2173 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_238_Fig3_HTML" id="MO5"/>
###xml 860 2174 860 2173 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="21">Transduction and intracellular localization of VLC-1-TAT in isolated adult cardiomyocytes. <bold>a</bold> Scheme for the application of the VLC-1-derived peptides and confocal imaging. Peptides were applied at a concentration of 1&#160;&#956;M, incubated for 15&#160;min to freshly isolated cardiomyocytes. After removal of the peptide solution, the cells were washed twice and kept in buffer or medium for direct live-cell confocal imaging microscopy. Subsequently, the transduced cardiomyocytes were electrically stimulated with 1&#160;Hz for maximally 1&#160;h. <bold>b</bold> The negative control peptide TAMRA-labeled VLC-1 stained only dead cardiomyocytes (low magnification, <italic>upper panel</italic>) but failed to get internalized into healthy cardiomyocytes even when 100% laser power was used to detect potentially weak signals (<italic>lower panel</italic>). <bold>c</bold> Application of TAT-VLC-1 to living cardiomyocytes led to rapid internalization of the peptide (<italic>upper panel</italic>). The <italic>lower panel</italic> shows transduced VLC-1-TAT at higher magnification in an overlay of the phase contrast and the TAMRA-fluorescence. The <italic>arrow</italic> indicates the direction of the intensity profile of <italic>gray</italic> and <italic>red</italic> intensities in the line scan for the localization analysis of VLC-1-TAT, which was present at sarcomeric structures with enrichment at the actin-containing I-bands (<italic>light bands</italic> in phase-contrast image)</p></caption><graphic position="anchor" xlink:href="109_2007_238_Fig3_HTML" id="MO5"/></fig>
To first test whether the VLC-1 peptide itself might be taken up by isolated cardiomyocytes because of its basic charge, VLC-1 and VLC-1-TAT were applied for 15 min to freshly isolated cardiomyocytes under resting conditions or, in another set of experiments, constant electric stimulation (1 Hz, 20 V). After the fluorescent peptides were washed away, the cells were analyzed live by confocal laser-scanning microscopy (Fig. 3a). VLC-1 alone was not internalized into healthy cardiomyocytes and stained only compromised cells (upper panel, Fig. 3b). To ensure that low concentrations of intracellular VLC-1 were not missed, the laser intensity was increased to its maximum, and still no fluorescent signals were measured (lower panel, Fig. 3b). In contrast, VLC-1-TAT reached the intracellular compartments of more than 95% of adult cardiomyocytes (Fig. 3c). Fig. 3Transduction and intracellular localization of VLC-1-TAT in isolated adult cardiomyocytes. a Scheme for the application of the VLC-1-derived peptides and confocal imaging. Peptides were applied at a concentration of 1 muM, incubated for 15 min to freshly isolated cardiomyocytes. After removal of the peptide solution, the cells were washed twice and kept in buffer or medium for direct live-cell confocal imaging microscopy. Subsequently, the transduced cardiomyocytes were electrically stimulated with 1 Hz for maximally 1 h. b The negative control peptide TAMRA-labeled VLC-1 stained only dead cardiomyocytes (low magnification, upper panel) but failed to get internalized into healthy cardiomyocytes even when 100% laser power was used to detect potentially weak signals (lower panel). c Application of TAT-VLC-1 to living cardiomyocytes led to rapid internalization of the peptide (upper panel). The lower panel shows transduced VLC-1-TAT at higher magnification in an overlay of the phase contrast and the TAMRA-fluorescence. The arrow indicates the direction of the intensity profile of gray and red intensities in the line scan for the localization analysis of VLC-1-TAT, which was present at sarcomeric structures with enrichment at the actin-containing I-bands (light bands in phase-contrast image)
###end p 20
###begin p 21
###xml 91 92 91 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 528 529 527 528 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 632 643 631 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 776 787 775 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 790 791 789 790 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 887 898 886 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 905 916 904 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 1036 1041 1035 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 1094 1098 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gray</italic>
###xml 1103 1106 1102 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1272 1283 1271 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">light bands</italic>
Transduction and intracellular localization of VLC-1-TAT in isolated adult cardiomyocytes. a Scheme for the application of the VLC-1-derived peptides and confocal imaging. Peptides were applied at a concentration of 1 muM, incubated for 15 min to freshly isolated cardiomyocytes. After removal of the peptide solution, the cells were washed twice and kept in buffer or medium for direct live-cell confocal imaging microscopy. Subsequently, the transduced cardiomyocytes were electrically stimulated with 1 Hz for maximally 1 h. b The negative control peptide TAMRA-labeled VLC-1 stained only dead cardiomyocytes (low magnification, upper panel) but failed to get internalized into healthy cardiomyocytes even when 100% laser power was used to detect potentially weak signals (lower panel). c Application of TAT-VLC-1 to living cardiomyocytes led to rapid internalization of the peptide (upper panel). The lower panel shows transduced VLC-1-TAT at higher magnification in an overlay of the phase contrast and the TAMRA-fluorescence. The arrow indicates the direction of the intensity profile of gray and red intensities in the line scan for the localization analysis of VLC-1-TAT, which was present at sarcomeric structures with enrichment at the actin-containing I-bands (light bands in phase-contrast image)
###end p 21
###begin p 22
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
Unlike the localization of the TAT and TAT-p21 peptides (Fig. 1), the VLC-1-TAT was not detected in the cell nucleus. Detailed analysis of the intracellular distribution of transduced VLC-1-TAT and correlation of the fluorescent signals with the phase contrast images (merge image, lower panel, Fig. 3c) demonstrated that the peptide associates with sarcomeric structures. It showed strong enrichment at the I-bands representing the nonoverlapping zones of the thin actin filaments with the thick myosin filaments (linescan, lower panel, Fig. 3c). After transduction, the VLC-1-TAT peptide remained inside the sarcomeric compartments of the cardiomyocytes for at least 1 h after transferring the loaded cardiomyocytes into the peptide-free buffer solution.
###end p 22
###begin p 23
###xml 213 215 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 468 470 466 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1186 1188 1184 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1436 1438 1434 1436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1516 1518 1514 1516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1591 1593 1589 1591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1726 1727 1724 1725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1731 1737 1729 1735 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1816 1817 1814 1815 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1856 1859 1854 1857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 1877 1879 1875 1877 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1923 1924 1921 1922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1957 1963 1955 1961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 2094 2095 2090 2091 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2226 2228 2221 2223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FS</italic>
###xml 2340 2341 2335 2336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2341 2344 2336 2339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 2382 2383 2377 2378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2383 2386 2378 2381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 2502 2503 2497 2498 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2663 2664 2657 2658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 2816 2817 2810 2811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2817 2820 2811 2814 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 2877 2878 2871 2872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2878 2881 2872 2875 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 3023 3024 3015 3016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 3092 3107 3084 3099 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Double asterisk</italic>
###xml 3109 3110 3101 3102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3119 3134 3111 3126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">triple asterisk</italic>
###xml 3136 3137 3128 3129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3147 3148 3139 3140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1737 3172 1735 3164 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">Functional effects of cell permeable VLC-1-TAT in living adult cardiomyocytes. <bold>a</bold> Original registration of cell length (<italic>top</italic>) and cytosolic Ca<sup>2+</sup> signals (Fura-2 signal, expressed as ratio <italic>R</italic> between 340 and 380 excitation; <italic>bottom</italic>) of electrically paced adult rat cardiomyocytes before (basal) and after incubation with 1&#160;&#956;M VLC-1-TAT or 1&#160;&#956;M TAT as control. <bold>b</bold> Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1&#160;&#956;M) on fractional shortening (<italic>FS</italic>; given in percent of basal contraction obtained before incubation with the peptide), maximal rate of FS (+dFS/d<italic>t</italic><sub>max</sub>), and maximal relaxation rate (-dFS/d<italic>t</italic><sub>max</sub>; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. <bold>c</bold> Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1&#160;&#956;M) on peak Fura-2 fluorescence signal (expressed as ratio <italic>R</italic> between 340 and 380 excitation, given in percent of basal R340/380 obtained before incubation with the peptide), maximal rate of R340/380 (+dR340/380/d<italic>t</italic><sub>max</sub>), and maximal rate of fluorescence decline (-dR340/380/d<italic>t</italic><sub>max</sub>; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. Values are means&#8201;&#177;&#8201;SEM, <italic>n</italic>&#8201;=&#8201;6&#8211;9 different cardiomyocytes at each peptide concentration used. <italic>Double asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.01; <italic>triple asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 (<italic>t</italic> test for paired values)</p>
###xml 1737 3172 1735 3164 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">Functional effects of cell permeable VLC-1-TAT in living adult cardiomyocytes. <bold>a</bold> Original registration of cell length (<italic>top</italic>) and cytosolic Ca<sup>2+</sup> signals (Fura-2 signal, expressed as ratio <italic>R</italic> between 340 and 380 excitation; <italic>bottom</italic>) of electrically paced adult rat cardiomyocytes before (basal) and after incubation with 1&#160;&#956;M VLC-1-TAT or 1&#160;&#956;M TAT as control. <bold>b</bold> Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1&#160;&#956;M) on fractional shortening (<italic>FS</italic>; given in percent of basal contraction obtained before incubation with the peptide), maximal rate of FS (+dFS/d<italic>t</italic><sub>max</sub>), and maximal relaxation rate (-dFS/d<italic>t</italic><sub>max</sub>; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. <bold>c</bold> Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1&#160;&#956;M) on peak Fura-2 fluorescence signal (expressed as ratio <italic>R</italic> between 340 and 380 excitation, given in percent of basal R340/380 obtained before incubation with the peptide), maximal rate of R340/380 (+dR340/380/d<italic>t</italic><sub>max</sub>), and maximal rate of fluorescence decline (-dR340/380/d<italic>t</italic><sub>max</sub>; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. Values are means&#8201;&#177;&#8201;SEM, <italic>n</italic>&#8201;=&#8201;6&#8211;9 different cardiomyocytes at each peptide concentration used. <italic>Double asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.01; <italic>triple asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 (<italic>t</italic> test for paired values)</p></caption>
###xml 3172 3172 3164 3164 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2007_238_Fig4_HTML" id="MO6"/>
###xml 1731 3172 1729 3164 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="24">Functional effects of cell permeable VLC-1-TAT in living adult cardiomyocytes. <bold>a</bold> Original registration of cell length (<italic>top</italic>) and cytosolic Ca<sup>2+</sup> signals (Fura-2 signal, expressed as ratio <italic>R</italic> between 340 and 380 excitation; <italic>bottom</italic>) of electrically paced adult rat cardiomyocytes before (basal) and after incubation with 1&#160;&#956;M VLC-1-TAT or 1&#160;&#956;M TAT as control. <bold>b</bold> Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1&#160;&#956;M) on fractional shortening (<italic>FS</italic>; given in percent of basal contraction obtained before incubation with the peptide), maximal rate of FS (+dFS/d<italic>t</italic><sub>max</sub>), and maximal relaxation rate (-dFS/d<italic>t</italic><sub>max</sub>; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. <bold>c</bold> Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1&#160;&#956;M) on peak Fura-2 fluorescence signal (expressed as ratio <italic>R</italic> between 340 and 380 excitation, given in percent of basal R340/380 obtained before incubation with the peptide), maximal rate of R340/380 (+dR340/380/d<italic>t</italic><sub>max</sub>), and maximal rate of fluorescence decline (-dR340/380/d<italic>t</italic><sub>max</sub>; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. Values are means&#8201;&#177;&#8201;SEM, <italic>n</italic>&#8201;=&#8201;6&#8211;9 different cardiomyocytes at each peptide concentration used. <italic>Double asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.01; <italic>triple asterisk</italic>, <italic>p</italic>&#8201;&lt;&#8201;0.001 (<italic>t</italic> test for paired values)</p></caption><graphic position="anchor" xlink:href="109_2007_238_Fig4_HTML" id="MO6"/></fig>
###xml 278 281 <span type="species:ncbi:10116">rat</span>
###xml 1993 1996 <span type="species:ncbi:10116">rat</span>
Using the same incubation protocol, we studied the effects of the cell-permeable VLC-1 peptide on muscle function by simultaneously monitoring the shortening amplitude and the systolic and diastolic cytoplasmic Ca2+ fluctuations (measured by Fura-2 fluorescence) of paced adult rat cardiomyocytes (Fig. 4a). As shown in Figs. 4b and c, 1 muM, but not 0.5 muM, of VLC-1-TAT significantly increased the shortening amplitude of adult cardiomyocyte, while the cytosolic Ca2+ signal remained unchanged. The same concentrations of control TAT peptide alone did not change the contractile state or the Fura-2 signals if compared to the basal state during the preincubation period. Higher concentrations of both control and test peptides induced deleterious effects on the cardiomyocyte contraction. It is interesting to note that not only the maximal amplitude of shortening rose but also the maximal rate of shortening and the maximal relaxation velocity increased significantly. Because the Fura-2 signal remained unchanged, the selective effect of the VLC-1-TAT peptide on the contraction parameters suggests a selective and direct effect on the function of the myosin cross-bridges. The Ca2+-sensitizing effect of the VLC-1-TAT peptide could be predicted from the mechanism of action, as the inhibition of the MLC-1/actin interaction may rise selectively myosin motor activity and therefore muscle contraction at a given activating free Ca2+ concentration, i.e., an inotropic effect without additional recruitment of Ca2+. It should be noted that the VLC-1-TAT peptide left the intracellular Ca2+-handling system unchanged, as seen by the fact that the kinetic parameters of the Fura-2 fluorescence signals remained normal (Fig. 4c). Fig. 4Functional effects of cell permeable VLC-1-TAT in living adult cardiomyocytes. a Original registration of cell length (top) and cytosolic Ca2+ signals (Fura-2 signal, expressed as ratio R between 340 and 380 excitation; bottom) of electrically paced adult rat cardiomyocytes before (basal) and after incubation with 1 muM VLC-1-TAT or 1 muM TAT as control. b Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1 muM) on fractional shortening (FS; given in percent of basal contraction obtained before incubation with the peptide), maximal rate of FS (+dFS/dtmax), and maximal relaxation rate (-dFS/dtmax; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. c Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1 muM) on peak Fura-2 fluorescence signal (expressed as ratio R between 340 and 380 excitation, given in percent of basal R340/380 obtained before incubation with the peptide), maximal rate of R340/380 (+dR340/380/dtmax), and maximal rate of fluorescence decline (-dR340/380/dtmax; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. Values are means +/- SEM, n = 6-9 different cardiomyocytes at each peptide concentration used. Double asterisk, p < 0.01; triple asterisk, p < 0.001 (t test for paired values)
###end p 23
###begin p 24
###xml 79 80 79 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 140 142 140 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 220 226 220 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 357 358 355 356 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 489 491 486 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FS</italic>
###xml 603 604 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 604 607 601 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 645 646 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 646 649 643 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 765 766 762 763 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 926 927 922 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1079 1080 1075 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1080 1083 1076 1079 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1140 1141 1136 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1141 1144 1137 1140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1286 1287 1280 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1355 1370 1349 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Double asterisk</italic>
###xml 1372 1373 1366 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1382 1397 1376 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">triple asterisk</italic>
###xml 1399 1400 1393 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1410 1411 1404 1405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 256 259 <span type="species:ncbi:10116">rat</span>
Functional effects of cell permeable VLC-1-TAT in living adult cardiomyocytes. a Original registration of cell length (top) and cytosolic Ca2+ signals (Fura-2 signal, expressed as ratio R between 340 and 380 excitation; bottom) of electrically paced adult rat cardiomyocytes before (basal) and after incubation with 1 muM VLC-1-TAT or 1 muM TAT as control. b Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1 muM) on fractional shortening (FS; given in percent of basal contraction obtained before incubation with the peptide), maximal rate of FS (+dFS/dtmax), and maximal relaxation rate (-dFS/dtmax; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. c Statistical evaluation of the effects of different concentrations of transducible peptides (0.5, 1 muM) on peak Fura-2 fluorescence signal (expressed as ratio R between 340 and 380 excitation, given in percent of basal R340/380 obtained before incubation with the peptide), maximal rate of R340/380 (+dR340/380/dtmax), and maximal rate of fluorescence decline (-dR340/380/dtmax; both given in percent of basal values obtained before peptide incubation) of control peptide (TAT) and VLC-1-TAT. Values are means +/- SEM, n = 6-9 different cardiomyocytes at each peptide concentration used. Double asterisk, p < 0.01; triple asterisk, p < 0.001 (t test for paired values)
###end p 24
###begin p 25
###xml 421 423 421 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 500 502 500 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
In summary, we demonstrate by live-cell microscopy that CPPs and CPPs fused to peptides were taken up by adult cardiomyocytes with high efficiency and localize to their targets inside the cytoplasm and/or nucleus. The cell-permeable peptide VLC-1-TAT accumulated in the actin-containing I-band of the sarcomeres and was able to enhance the contractility of isolated adult cardiomyocytes without changing the myoplasmic Ca2+ levels. Importantly, the fact that VLC-1-TAT did not affect intracellular Ca2+ concentration and that it only has targets in striated muscle cells makes this peptide uniquely suited as a novel potential therapeutic tool to modulate heart function. VLC-1-TAT is a powerful new drug candidate to improve the contractile state of the failing heart.
###end p 25
###begin p 26
We thank W.-P. Schlegel and P. Pierschalek for technical assistance, R.M. Martin for invaluable help with confocal microscopy, and Jeff Stear for comments. G.T. was supported by the European Union (ESF Program). This work was funded in part by grants of the Deutsche Forschungsgemeinschaft and the Volkswagen Foundation to M.C.C and Deutsche Forschungsgemeinschaft to I.M.
###end p 26
###begin title 27
References
###end title 27
###begin article-title 28
###xml 19 22 <span type="species:ncbi:10116">rat</span>
Calcium current in rat cardiomyocytes is modulated by the carboxyl-terminal ahnak domain
###end article-title 28
###begin article-title 29
Molecular modeling of the myosin-S1(A1) isoform
###end article-title 29
###begin article-title 30
###xml 98 101 <span type="species:ncbi:10116">rat</span>
Unloaded shortening velocity and myosin heavy chain and alkali light chain isoform composition in rat skeletal muscle fibres
###end article-title 30
###begin article-title 31
Peptides derived from the C2 domain of protein kinase C epsilon (epsilon PKC) modulate epsilon PKC activity and identify potential protein-protein interaction surfaces
###end article-title 31
###begin article-title 32
Protein transduction: a novel tool for tissue regeneration
###end article-title 32
###begin article-title 33
Interaction of isozymes of myosin subfragment 1 with actin: effect of ionic strength and nucleotide
###end article-title 33
###begin article-title 34
Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC
###end article-title 34
###begin article-title 35
Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7)
###end article-title 35
###begin article-title 36
Calpain and mitochondria in ischemia/reperfusion injury
###end article-title 36
###begin article-title 37
Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis
###end article-title 37
###begin article-title 38
Trojan peptides: the penetrating system for intracellular delivery
###end article-title 38
###begin article-title 39
###xml 58 63 <span type="species:ncbi:9796">horse</span>
Delivery of bioactive molecules into the cell: the Trojan horse approach
###end article-title 39
###begin article-title 40
Cellular uptake of Antennapedia Penetratin peptides is a two-step process in which phase transfer precedes a tryptophan-dependent translocation
###end article-title 40
###begin article-title 41
Tat-mediated delivery of heterologous proteins into cells
###end article-title 41
###begin article-title 42
###xml 47 71 <span type="species:ncbi:44689">Dictyostelium discoideum</span>
X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4
###end article-title 42
###begin article-title 43
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human ventricular/slow twitch myosin alkali light chain gene characterization, sequence, and chromosomal location
###end article-title 43
###begin article-title 44
###xml 40 68 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Cellular uptake of the tat protein from human immunodeficiency virus
###end article-title 44
###begin article-title 45
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery
###end article-title 45
###begin article-title 46
Structural mechanism of muscle contraction
###end article-title 46
###begin article-title 47
###xml 56 84 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein
###end article-title 47
###begin article-title 48
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 113 117 <span type="species:ncbi:10116">rats</span>
Minigenes encoding N-terminal domains of human cardiac myosin light chain-1 improve heart function of transgenic rats
###end article-title 48
###begin article-title 49
###xml 53 81 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein
###end article-title 49
###begin article-title 50
Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo
###end article-title 50
###begin article-title 51
Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator
###end article-title 51
###begin article-title 52
Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate
###end article-title 52
###begin article-title 53
###xml 111 114 <span type="species:ncbi:10116">rat</span>
BH4 peptide derivative from Bcl-xL attenuates ischemia/reperfusion injury thorough anti-apoptotic mechanism in rat hearts
###end article-title 53
###begin article-title 54
Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake
###end article-title 54
###begin article-title 55
Apoptosis-modulating interaction of the neuregulin/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes
###end article-title 55
###begin article-title 56
###xml 46 74 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Structural and functional characterization of human immunodeficiency virus tat protein
###end article-title 56
###begin article-title 57
Histones and basic polyamino acids stimulate the uptake of albumin by tumor cells in culture
###end article-title 57
###begin article-title 58
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human embryonic/atrial myosin alkali light chain gene: characterization, sequence, and chromosomal location
###end article-title 58
###begin article-title 59
###xml 65 89 <span type="species:ncbi:44689">Dictyostelium discoideum</span>
X-ray structure of the magnesium(II).ADP.vanadate complex of the Dictyostelium discoideum myosin motor domain to 1.9 A resolution
###end article-title 59
###begin article-title 60
Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells
###end article-title 60
###begin article-title 61
Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase
###end article-title 61
###begin article-title 62
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 42 45 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis
###end article-title 62
###begin p 63
M. Cristina Cardoso and Ingo Morano contributed equally.
###end p 63

